106 related articles for article (PubMed ID: 16249349)
1. Topotecan: weighing in when there are many options.
Penson RT; Seiden MV
Oncologist; 2005 Oct; 10(9):698-700. PubMed ID: 16249349
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.
Gralla RJ
Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146
[TBL] [Abstract][Full Text] [Related]
3. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
4. Topotecan in the first-line treatment of small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():33-42. PubMed ID: 15616148
[TBL] [Abstract][Full Text] [Related]
5. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
Markman M
Oncologist; 2007 Feb; 12(2):186-90. PubMed ID: 17296814
[TBL] [Abstract][Full Text] [Related]
6. Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity.
Markman M
Oncologist; 2005 Oct; 10(9):695-7. PubMed ID: 16249348
[TBL] [Abstract][Full Text] [Related]
7. Topotecan for the treatment of small-cell lung cancer.
Nicum SJ; O'Brien ME
Expert Rev Anticancer Ther; 2007 Jun; 7(6):795-801. PubMed ID: 17555389
[TBL] [Abstract][Full Text] [Related]
8. Recent advances with topotecan in the treatment of lung cancer.
O'Brien M; Eckardt J; Ramlau R
Oncologist; 2007 Oct; 12(10):1194-204. PubMed ID: 17962613
[TBL] [Abstract][Full Text] [Related]
9. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Ettinger DS
Semin Oncol; 2001 Apr; 28(2 Suppl 4):27-9. PubMed ID: 11479894
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy.
Spannuth WA; Leath CA; Huh WK; Barnes MN; Davidson SA; Kilgore LC; Partridge EE; Austin JM; Alvarez RD
Gynecol Oncol; 2007 Mar; 104(3):591-5. PubMed ID: 17045635
[TBL] [Abstract][Full Text] [Related]
11. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
13. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
[TBL] [Abstract][Full Text] [Related]
14. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
15. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
18. Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients.
Coleman RL; Gordon A; Barter J; Sun S; Rackoff W; Herzog TJ
Oncologist; 2007 Jan; 12(1):72-8. PubMed ID: 17227902
[TBL] [Abstract][Full Text] [Related]
19. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]